Q2 2024 Aquestive Therapeutics Inc Earnings Call Transcript
Key Points
- Aquestive Therapeutics Inc (AQST) progressed its Anaphylm epinephrine Sublingual Film program and gained FDA approval for Libervant diazepam Buccal Film for the 2 to 5-year-old age group.
- The company successfully completed two of the three supportive studies necessary for engaging the FDA in a pre-NDA meeting for Anaphylm, with positive top-line data.
- Aquestive Therapeutics Inc (AQST) reported a 52% increase in total revenues year-over-year, driven by increases in license and royalty revenue.
- The company has $90 million in cash and cash equivalents as of June 30, 2024, providing a strong financial position to support ongoing development and commercialization efforts.
- Aquestive Therapeutics Inc (AQST) is expanding its commercial launch activities for Libervant, with national retail distribution capabilities expected by October 1 and a national sales team expansion in late Q3.
- Despite the revenue increase, excluding the one-time recognition of deferred revenue, total revenues actually decreased by 26% year-over-year.
- Research and development expenses increased significantly, from $3.5 million in Q2 2023 to $4.2 million in Q2 2024, primarily due to clinical trial costs and increased personnel costs.
- Selling, general, and administrative expenses also saw a substantial rise, increasing by 54% year-over-year, driven by higher personnel costs, share-based compensation, and regulatory fees.
- The net loss for the six months ended June 30, 2024, was $15.6 million, a significant increase compared to the net income of $2.3 million for the same period in 2023.
- The company terminated its US and China-based collaborations for Exservan, which had negligible revenue in 2023, indicating a strategic shift but also a potential loss of future revenue streams.
Good morning and welcome to the Aquestive Therapeutics second quarter 2024 conference call. (Operator Instructions) As a reminder, this call will be recorded. I would now like to introduce your host for today's conference call Bennett Watson, of ICR Westwicke Investor Relations. You may begin.
Thank you, operator. Good morning and welcome to today's call. On today's call, I'm joined by Dan Barber, Chief Executive Officer; and Ernie Toth, Chief Financial Officer. Who are going to provide an overview of recent business developments and performance for the second quarter 2024, followed by a Q&A session. During the Q&A session, the team will be joined by Dr. Carl Kraus, Chief Medical Officer; Dr. Stephen Wargacki, Chief Science Officer; and Sherry Korczynski, Senior Vice President of Sales and Marketing.
As a reminder, the company's remarks today correspond with the earnings release that was issued after market close yesterday. In addition, a recording of today's call will be made available on a quest as website
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
